DCGI approves mRNA Covid jab for 18 yrs & above; Covovax for 7-11 yrs

The Drugs Controller General of India on Tuesday approved India's first indigenously developed mRNA vaccine against COVID-19 manufactured by Gennova Biopharmaceuticals for restricted emergency use......

Gennova's mRNA vaccine to come in powder form, stay stable at 2-8C

Gennova has also got permission for phase-2 and 3 clinical trials for its lyophilised mRNA vaccine for injection from the subject expert committee advising the Central Drugs Standards Control......

Gennova's mRNA Covid vaccine gets nod for Phase 2-3 trials

If things go according to plan, the vaccine would be available in the market by the end of this year. IMAGE: Kindly note that this image has been posted for representational purposes only.......

Govt exploring possibility to produce Covaxin abroad

To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously......

The future belongs to biopharma. Can India catch up with China?

If we are to realise the full potential of biologics' ability to improve people's health, it is essential to encourage public policy and support R&D. IMAGE: It’s been evident for a decade......

Start-up frenzy reflects a herd-like mentality: Kiran Mazumdar-Shaw

'I have learnt that gender discrimination obliterates when you succeed and overcome credibility and perception hurdles' India wasn't ready for a woman brewmaster in the 1970s when Kiran Mazumdar......

US pharma companies want dialogue with India on IPRs

Top executives of American pharma companies favour "dialogue" with India and "not confrontation" to address their concerns on key issues like the protection of intellectual property (IP) and......

IP environment deteriorating in India: US pharma industry

The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied. "PhRMA remains......